Cardio3 BioSciences, an international Mayo Clinic collaborator, has received FDA approval for a Phase 3 pivotal clinical trial of its stem cell therapy.
The trial will test the Mayo Clinic discovery of cardiopoietic (cardiogenically-instructed) stem cells designed to improve heart health in people suffering from heart failure. The multi-site U.S. trial, called CHART-2, will aim to recruit 240 patients with chronic advanced symptomatic heart failure. Cardio3 BioSciences is a bioscience company in Mont-Saint-Guibert, Belgium.
“Regenerative medicine is poised to transform the way we treat patients,” said Andre Terzic, director of the Mayo Clinic Center for Regenerative Medicine.
Date: January 20, 2014
Source: Mayo Clinic
Filed Under: Drug Discovery
